Two layers sit on every record. A panel of named AI models comments on what is right, what is missing and what is disputed, each claim tied to the record's own sources: machine commentary, not clinical review. Human reviewers sign pages off on top of it. 15,616 pages are open for a named human review and none has one yet; the queue below ranks them by reach, stakes and staleness.
Each model on the panel reads a record and its linked records, then returns verdicts on the record's own claims: right (stated and backed by the source), disputed, missing or unclear. Model name, version and date are shown on every card and sources come only from the record's own links. Hand-written illustrations carry an Example badge.
Machine commentary by named AI models on a date, not clinical review. Claims are tied to the record's own sources; check them before relying on anything here.
| Model | Provider | Version | Records reviewed | Latest |
|---|---|---|---|---|
| Fable | Anthropic | claude-fable-5-1 · v5.1 | 21 | 2026-10-06 |
| Astra | Anthropic | claude-opus-5 · v5 | 1 | 2026-10-06 |
The panel table lives in src/lib/model-reviews.ts; reviews are written by scripts/model-reviews.ts to public/reviews/models/, one JSON file per record, and validated when the site is built.
Records with commentary, those that split the panel first. A split means two models gave the same claim different stances; the record page shows each position with its source.
Named clinicians, scientists, regulatory specialists and patient advocates sign pages off on top of the model panel. A human review is a statement about a page on a date and is the only review OnCo treats as clinical.
| Kind | |||||
|---|---|---|---|---|---|
| Trial | 6,143 | 0 | 0 | 0 (0%) | Expert (clinical) |
| Key paper | 2,632 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Target | 1,694 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Term | 1,229 | 0 | 0 | 0 (0%) | Patient advocate |
| Idea | 1,224 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Treatment | 1,141 | 0 | 0 | 0 (0%) | Expert (regulatory), Expert (clinical), Patient advocate |
| Technology | 771 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Cancer | 474 | 0 | 0 | 0 (0%) | Expert (clinical), Patient advocate |
| Pathway | 109 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Pairing | 86 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Bottleneck | 54 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Roadmap | 39 | 0 | 0 | 0 (0%) | Expert (scientific) |
| Front | 20 | 0 | 0 | 0 (0%) | Patient advocate |
Companies, institutions, people, collections and journals are attributed (who wrote the record) rather than reviewed; organisations correct their own records through Suggest an edit.
Score out of 100: reach (graph connections, log-scaled, up to 40), stakes (evidence score or a kind default, up to 30), staleness (days since the record's asOf, a year is 30). Pages already reviewed on every track they need within a year sort to the bottom.
| Page | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1 | Cancer | Acute lymphoblastic leukaemia | 75 | 570 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 2 | Cancer | Acute myeloid leukaemia | 75 | 716 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 3 | Technology | Anti-angiogenic therapy | 75 | 293 | 99 | 57 d | Expert (scientific) | Review this page |
| 4 | Cancer | Biliary tract cancer (cholangiocarcinoma) | 75 | 540 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 5 | Cancer | Brain and spinal cord tumours (all types) | 75 | 146 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 6 | Cancer | Childhood cancers (all types) | 75 | 124 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 7 | Cancer | Chronic lymphocytic leukaemia | 75 | 444 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 8 | Technology | Cytotoxic chemotherapy | 75 | 1,418 | 99 | 57 d | Expert (scientific) | Review this page |
| 9 | Cancer | Extragonadal germ cell tumour | 75 | 41 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 10 | Cancer | Head and neck squamous cell carcinoma | 75 | 776 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 11 | Cancer | Hepatocellular carcinoma | 75 | 658 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 12 | Technology | Immune checkpoint inhibitors | 75 | 1,718 | 99 | 57 d | Expert (scientific) | Review this page |
| 13 | Cancer | Melanoma | 75 | 1,004 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 14 | Cancer | Metastatic cancer (cancer that has spread) | 75 | 747 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 15 | Technology | Monoclonal antibodies | 75 | 549 | 99 | 57 d | Expert (scientific) | Review this page |
| 16 | Cancer | Neuroendocrine tumours | 75 | 366 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 17 | Cancer | Thyroid cancer | 75 | 321 | n/a | 57 d | Expert (clinical), Patient advocate | Review this page |
| 18 | Cancer | Acral melanoma | 74 | 69 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 19 | Cancer | Acute myeloid leukaemia in children | 74 | 86 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 20 | Cancer | Acute myeloid leukaemia in older or unfit patients | 74 | 78 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 21 | Cancer | Acute promyelocytic leukaemia | 74 | 48 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 22 | Cancer | Adenoid cystic carcinoma | 74 | 47 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 23 | Cancer | Adolescent and young adult cancers (ages 15 to 39) | 74 | 71 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 24 | Cancer | Adrenocortical carcinoma | 74 | 71 | n/a | 53 d | Expert (clinical), Patient advocate | Review this page |
| 25 | Cancer | Advanced and metastatic adrenocortical carcinoma (ENSAT stage IV or unresectable) | 74 | 67 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
| 26 | Cancer | Advanced and metastatic small bowel adenocarcinoma | 74 | 59 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
| 27 | Cancer | Advanced hepatocellular carcinoma (BCLC C) | 74 | 127 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 28 | Cancer | Advanced melanoma (unresectable stage III and stage IV) | 74 | 204 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 29 | Cancer | Advanced or recurrent endometrial cancer | 74 | 93 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 30 | Cancer | Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia) | 74 | 61 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
| 31 | Cancer | Advanced-stage classical Hodgkin lymphoma (stage III to IV) | 74 | 201 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
| 32 | Cancer | ALK-positive non-small-cell lung cancer | 74 | 153 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 33 | Cancer | Alveolar soft part sarcoma | 74 | 41 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 34 | Cancer | Ampullary cancer (ampulla of Vater) | 74 | 83 | n/a | 51 d | Expert (clinical), Patient advocate | Review this page |
| 35 | Cancer | Anal cancer (squamous cell carcinoma) | 74 | 96 | n/a | 53 d | Expert (clinical), Patient advocate | Review this page |
| 36 | Cancer | Anal high-grade squamous intraepithelial lesions (precursor) | 74 | 41 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
| 37 | Cancer | Anaplastic thyroid cancer | 74 | 33 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 38 | Technology | Androgen deprivation & AR pathway inhibitors | 74 | 127 | 96 | 57 d | Expert (scientific) | Review this page |
| 39 | Cancer | Angiosarcoma | 74 | 53 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 40 | Cancer | Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell) | 74 | 62 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
| 41 | Cancer | Appendiceal cancer and pseudomyxoma peritonei | 74 | 39 | n/a | 53 d | Expert (clinical), Patient advocate | Review this page |
| 42 | Cancer | Astrocytoma, IDH-mutant (grades 2 to 4) | 74 | 97 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 43 | Treatment | Atezolizumab | 74 | 301 | 98 | 57 d | Expert (regulatory), Expert (clinical), Patient advocate | Review this page |
| 44 | Cancer | Atypical teratoid/rhabdoid tumour (ATRT) | 74 | 65 | n/a | 51 d | Expert (clinical), Patient advocate | Review this page |
| 45 | Cancer | Biliary tract cancer (all types) | 74 | 228 | n/a | 44 d | Expert (clinical), Patient advocate | Review this page |
| 46 | Technology | Biosimilar manufacturing and comparability | 74 | 33 | 99 | 44 d | Expert (scientific) | Review this page |
| 47 | Technology | Bispecific antibodies | 74 | 255 | 95 | 57 d | Expert (scientific) | Review this page |
| 48 | Cancer | Bladder & urothelial cancer | 74 | 646 | n/a | 54 d | Expert (clinical), Patient advocate | Review this page |
| 49 | Cancer | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) | 74 | 35 | n/a | 53 d | Expert (clinical), Patient advocate | Review this page |
| 50 | Cancer | Borderline resectable pancreatic ductal adenocarcinoma | 74 | 151 | n/a | 43 d | Expert (clinical), Patient advocate | Review this page |
Showing the top 50 of 15,616 reviewable pages.
The ten highest-need pages for each track, so a clinician, a scientist, a regulatory specialist or an advocate can start without reading the whole queue.
Standard-of-care rows against current NCCN and ESMO guidance; trial figures against the primary publication.
Mechanism, biology and evidence tier accurately stated; nothing speculative presented as settled.
Approval dates, regions and indications match the label or agency notice.
TL;DR, simple text and questions clear, non-alarming and accurate at the stated reading level.
Every translated TL;DR is machine-assisted until a named speaker of the language reviews it. Pages show MT until then and Reviewed after. Reviews are recorded in src/data/i18n/reviewed.ts.
| Language | Translated TL;DRs | Reviewed | Reviewers | |
|---|---|---|---|---|
| Spanish Español | 7,260 | 0 (0%) | 0 | Review translations |
| Chinese 中文 | 11,819 | 0 (0%) | 0 | Review translations |
| Portuguese Português | 7,260 | 0 (0%) | 0 | Review translations |
| Hindi हिन्दी | 7,260 | 0 (0%) | 0 | Review translations |
| French Français | 7,260 | 0 (0%) | 0 | Review translations |
| German Deutsch | 7,260 | 0 (0%) | 0 | Review translations |
| Japanese 日本語 | 7,260 | 0 (0%) | 0 | Review translations |
| Arabic العربية | 7,260 | 0 (0%) | 0 | Review translations |
Spotted a wrong translation on one page? Use Translation fix; to sign off a batch, Translation review.
src/data/reviews.ts. The badge appears on the page with your name, the date and your COI statement, and you appear on the roster.A review is a statement about a page on a date, not an endorsement. Nothing is edited directly by reviewers or by anyone else: every change enters as an issue and is checked before it is merged. Tracks and verification rules: REVIEWERS.md.